Related references
Note: Only part of the references are listed.Palliation of malignant ascites
Caitlin Hodge et al.
JOURNAL OF SURGICAL ONCOLOGY (2019)
Clinical Guidelines for Management of Gastrointestinal Symptoms in Cancer Patients: The Japanese Society of Palliative Medicine Recommendations
Takayuki Hisanaga et al.
JOURNAL OF PALLIATIVE MEDICINE (2019)
Efficacy and safety of reinfusion of concentrated ascitic fluid for malignant ascites: a concept-proof study
Rumi Hanada et al.
SUPPORTIVE CARE IN CANCER (2018)
The clinical significance of vascular endothelial growth factor in malignant ascites
Na Zhan et al.
TUMOR BIOLOGY (2016)
Malignant Pleural Effusion and ascites Induce Epithelial-Mesenchymal Transition and Cancer Stem-like Cell Properties via the Vascular Endothelial Growth Factor (VEGF)/Phosphatidylinositol 3-Kinase (PI3K)/Akt/Mechanistic Target of Rapamycin (mTOR) Pathway
Tao Yin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Comfort Care for Patients Dying in the Hospital
Craig D. Blinderman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effects of cell-free and concentrated ascites reinfusion therapy (CART) on symptom relief of malignancy-related ascites
Tetsuya Ito et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2015)
A survey of treatment approaches of malignant ascites in Germany and Austria
C. F. Jehn et al.
SUPPORTIVE CARE IN CANCER (2015)
Pilot Study of Intraperitoneal Administration of Triamcinolone Acetonide for Cancerous Ascites in Patients With End-Stage Gynecological Cancer
Tadahiro Shoji et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2014)
Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer
Martin R. Stockler et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Malignant ascites: pathophysiology and treatment
Emanuel Cavazzoni et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2013)
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study
Walter H. Gotlieb et al.
LANCET ONCOLOGY (2012)
Multiple imputation using chained equations: Issues and guidance for practice
Ian R. White et al.
STATISTICS IN MEDICINE (2011)
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial
Markus M. Heiss et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
The ability of existing questionnaires to measure symptom change after paracentesis for symptomatic ascites
Alexandra M. Easson et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Pattern and prognostic factors in patients with malignant ascites: a retrospective study
A. A. Ayantunde et al.
ANNALS OF ONCOLOGY (2007)
Malignant ascites: Systematic review and guideline for treatment
G Becker et al.
EUROPEAN JOURNAL OF CANCER (2006)
The development of clinical guidelines on paracentesis for ascites related to malignancy
J Stephenson et al.
PALLIATIVE MEDICINE (2002)
A phase II trial of triamcinolone hexacetanide for symptomatic recurrent malignant ascites
JR Mackey et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2000)
Paracentesis - an effective method of symptom control in the palliative care setting?
P McNamara
PALLIATIVE MEDICINE (2000)
Share Paper
